Skip to main content

The nuclear medicine department of the Institut Jules Bordet offers patients diagnostic tests of the functional or molecular type, as well as treatments with targeted molecular radiotherapy.  

The diagnostic tests differ from those carried out in the Radiology Department in that they involve the intravenous administration of substances labelled with radioactive isotopes, which specifically make it possible to identify the functionality or characteristic of an organ or of the cancer.

Therapeutic applications in nuclear medicine (often called “molecular radiotherapy”) use the same type of substance (tracer) specifically targeting the cancer tissue, but this substance is labelled with radioactive isotopes which emit therapeutic particles of the beta or alpha type enabling the destruction of the diseased cells.

Research projects

Project 1

Predicting the therapeutic result of 177Lu-octreotate (PRRT) using hybrid imaging in the case of refractory neuroendocrine tumours (LuMen)

Project 2

Somatostatin receptors imaging in relapsing and refractory multiple myeloma patients.

Project 3

Phase II prospective, multicentre study evaluating the utility of a an HER2-PET/CT combined with an FDG-PET/CT in identifying HER2 negative lesions that will not benefit from a new targeted treatment against HER2 : T-DM1 (ZEPHIR)
  • Project leader(s): Géraldine GebhartPatrick Flamen
  • Collaboration(s): Roche, Belgian and Dutch university hospital and centres  
  • Financing/Support : Roche

Project 4


Project 5

Molecular imaging of the tumor microenvironment

Project 6

Lutetium-177 dosimetry as a predictive biomarker of response in metastatic castrate resistant prostate cancer patients treated with psma radioligand therapy. the ludopath trial

Project 7


Our team

Head of Department
- Prof Patrick Flamen

The team
- Dr Géraldine Gebhart, H
ead of Clinic
- Dr Carlos ArtigasAssistant Head of Clinic
Dr Ioannis KarfisAssistant Head of Clinic
- Dr Elçin ÖzalpAssistant Head of Clinic
- Dr Erwin WoffAssistant Head of Clinic
- Dr Ivan Duran Derijckere, Resident

Radiophysicists (Department of Radiophysics)
Bruno Vanderlinden, Radiophysicist
Clémentine Marin, Radiophysicist 
Gwennaëlle MarinRadiophysicist

Physics control
Marie Christiane Yimo-Wadje

- Prof. 
Zéna WimanaManager Radiopharmacy
- Prof. Ghanem Ghanem
- Adriana De Matos, Operator Radiopharmacy
- Kadidja Ouldadda, Operator Radiopharmacy

Coordination of radionuclide treatments
- Marie-Noëlle Gheeraert
- Pauwel Thijs

Research Unit
- Prof. Zéna Wimana, Radiopharmacy/pre-clinical imaging
- Wendy Delbart, PhD Student/Research Assistant/ Biomedical Sciences, ULB
Loubna Taraji Schiltz, Clinical Study Coordinator
- Magdalena Mileva, MD, PhD Student/ Biomedical Sciences, ULB

- Qaid Shagera, MD, PhD Student/ Biomedical Sciences, ULB
- Ester Vicastillo Paredes, PhD Student/ Biomedical Sciences, ULB
- Gabriela Critchi,
Research Assistant

Sara Coelho, Head of Technologists

Jessie Toussaint
Anandi Henriet
Alyssa Hammouda (PET-Scan)


 Scientific publications

Lymphoscintigraphic Investigations for Axillary Web Syndromes.

Authors : Roman MM, Barbieux R, Eddy C, Karler C, Veys I, Zeltzer A, Adriaenssens N, Leduc O, Bourgeois P
Year : 2021
Journal : Lymphat Res Biol

<sup>68</sup>Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.

Authors : Shagera QA, Artigas C, Karfis I, Critchi G, Martinez Chanza N, Sideris S, Peltier A, Paesmans M, Gil T, Flamen P
Year : 2021
Journal : J Nucl Med

Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.

Authors : Bianchi L, Castellucci P, Farolfi A, Droghetti M, Artigas C, Leite J, Corona P, Shagera QA, Moreira R, González C, Queiroz M, de Galiza Barbosa F, Schiavina R, Deandreis D, Fanti S, Ceci F
Year : 2021
Journal : Eur Urol Oncol

131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.

Authors : Jungels C, Karfis I
Year : 2021
Journal : Curr Opin Oncol
Volume : 33
Pages : 33-39

Absence of residual fluorescence in the surgical bed at near-infrared fluorescence imaging predicts negative margins at final pathology in patients treated with breast-conserving surgery for breast cancer.

Authors : Pop FC, Veys I, Vankerckhove S, Barbieux R, Chintinne M, Moreau M, Donckier V, Larsimont D, Bourgeois P, Liberale G
Year : 2021
Journal : Eur J Surg Oncol
Volume : 47
Pages : 269-275